Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

Reed Smith attorney Rachael Pontikes will lead a Legal Update CE session at APC’s Compounders on Capitol Hill on November 2.

The session will focus on a number of hot compounding policy topics. Pontikes, as you may know, is the attorney representing seven compounding pharmacies in a lawsuit against the FDA’s MOU. She also led a Freedom of Information Act request that uncovered how FDA manipulated the structure and recommendations of NASEM’s 2020 cBHT report.

You won’t want to miss her perspective on these issues and legal considerations for compounders. All that and Hill visits, too! Get registered for CCH today!